The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

These drugs tend to be relatively ineffective, relatively toxic, or both. (Note that in some patients, getting rid of the atrial fibrillation with an ablation procedure is feasible.) The thing ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Doylestown Health is broadening its treatment options for atrial fibrillation patients with a revolutionary system that ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...